Literature DB >> 17999716

Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients.

J P Gisbert1, J-L Gisbert, S Marcos, I Jimenez-Alonso, R Moreno-Otero, J M Pajares.   

Abstract

BACKGROUND: Several 'rescue' therapies have been recommended to eradicate Helicobacter pylori, but they still fail in >20% of the cases, and these patients constitute a therapeutic dilemma. AIM: To evaluate the efficacy of different 'rescue' therapies empirically prescribed during 10 years to 500 patients in whom at least one eradication regimen had failed to cure H. pylori infection.
DESIGN: Prospective single-centre study. PATIENTS: Consecutive patients in whom at least one eradication regimen had failed. INTERVENTION: Rescue regimens included: (i) quadruple therapy with omeprazole-bismuth-tetracycline-metronidazole; (ii) ranitidine bismuth citrate-tetracycline-metronidazole; (iii) omeprazole-amoxicillin-levofloxacin; and (iv) omeprazole-amoxicillin-rifabutin. Antibiotic susceptibility was unknown (rescue regimens were chosen empirically). OUTCOME: Eradication was defined as a negative (13)C-urea breath test 4-8 weeks after completing therapy.
RESULTS: Five hundred patients were included (76% functional dyspepsia, 24% peptic ulcer). Compliance rates with first-, second- and third-line regimens were 92%, 92%, and 95%, respectively. Adverse effects were reported by 30%, 37%, and 55% of the patients receiving second-, third-, and fourth-line regimens. Overall, H. pylori cure rates with the second-, third-, and fourth-line rescue regimens were 70%, 74%, and 76%, respectively. Cumulative H. pylori eradication rate with four successive treatments was 99.5%.
CONCLUSION: It is possible to construct an overall treatment strategy to maximize H. pylori eradication, on the basis of administration of four consecutive empirical regimens; thus, performing bacterial culture even after a second or third eradication failure may not be necessary.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17999716     DOI: 10.1111/j.1365-2036.2007.03573.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  27 in total

1.  Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection.

Authors:  Sander Veldhuyzen van Zanten; Snehal Desai; Linda Best; Geraldine Cooper-Lesins; Dickran Malatjalian; David Haldane; Kevork Peltekian
Journal:  Can J Gastroenterol       Date:  2010-05       Impact factor: 3.522

2.  Eradication of H. pylori Infection: the Challenge is on if Standard Therapy Fails.

Authors:  Ulrich R M Bohr; Peter Malfertheiner
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

3.  Second-line rescue therapy of helicobacter pylori infection.

Authors:  Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

4.  The oligo-acyl lysyl antimicrobial peptide C₁₂K-2β₁₂ exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori.

Authors:  Morris O Makobongo; Hanan Gancz; Beth M Carpenter; Dennis P McDaniel; D Scott Merrell
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

Review 5.  "Rescue" regimens after Helicobacter pylori treatment failure.

Authors:  Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

6.  Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.

Authors:  J P Gisbert; A Perez-Aisa; L Rodrigo; J Molina-Infante; I Modolell; F Bermejo; M Castro-Fernández; R Antón; B Sacristán; A Cosme; J Barrio; Y Harb; M Gonzalez-Barcenas; M Fernandez-Bermejo; A Algaba; A C Marín; A G McNicholl
Journal:  Dig Dis Sci       Date:  2013-10-15       Impact factor: 3.199

7.  Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study.

Authors:  Hideki Mori; Hidekazu Suzuki; Juntaro Matsuzaki; Hitoshi Tsugawa; Seiichiro Fukuhara; Sawako Miyoshi; Kenro Hirata; Takashi Seino; Misako Matsushita; Toshihiro Nishizawa; Tatsuhiro Masaoka; Takanori Kanai
Journal:  United European Gastroenterol J       Date:  2015-11-13       Impact factor: 4.623

8.  [Clinical practice guideline on the management of patients with dyspepsia. Update 2012].

Authors:  Javier P Gisbert; Xavier Calvet; Juan Ferrándiz; Juan Mascort; Pablo Alonso-Coello; Mercè Marzo
Journal:  Aten Primaria       Date:  2012-10-01       Impact factor: 1.137

Review 9.  Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line.

Authors:  Simona Di Caro; Lucia Fini; Yayha Daoud; Fabio Grizzi; Antonio Gasbarrini; Antonino De Lorenzo; Laura Di Renzo; Sara McCartney; Stuart Bloom
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

10.  In vitro antibacterial activity of acyl-lysyl oligomers against Helicobacter pylori.

Authors:  Morris O Makobongo; Tchelet Kovachi; Hanan Gancz; Amram Mor; D Scott Merrell
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.